Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A composition for treating diabetes or diabesity comprising oxyntomodulin analog

a technology of oxyntomodulin and diabesity, which is applied in the direction of peptide/protein ingredients, extracellular fluid disorder, metabolic disorder, etc., can solve the problems of increasing the risk of retinopathy, neuropathy, neuropathy caused by vascular disorder, etc., and achieves high activity to activate, reduce blood glucose levels, and increase insulin secretion

Inactive Publication Date: 2015-10-22
HANMI PHARMA
View PDF3 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention describes an oxyntomodulin analog that can activate GLP-1 and glucagon receptors with high efficiency. This analog also expands beta-cells and increases insulin secretion, reducing blood glucose levels caused by a high-calorie and high-fat diet. Additionally, it decreases body weight and diet intake to improve insulin sensitivity and maintain blood glucose levels at normal levels. Therefore, this analog can be used for the prevention or treatment of diabetes and related diseases.

Problems solved by technology

If a chronic hyperglycemic condition is not suitably treated, it leads to various pathological conditions in the body.
Typically, it increases the risk of retinopathy, renal dysfunction, neuropathy, stroke caused by vascular disorder, kidney or heart diseases, diabetic foot ulcer, and cardiovascular disease.
Such complications reduce the quality of life, and eventually reduce the life expectancy of diabetic patients.
However, diet therapy or exercise therapy is difficult to control and implement strictly, and the therapeutic effect thereof is also insufficient.
However, it has shortcomings, including a fearful feeling for hypodermic needles, difficulty in administration, risk of hypoglycaemia, and an increase in weight.
However, these drugs were reported to have side effects, including hepatotoxicity, gastrointestinal disorder, cardiovascular disease and carcinogenesis, and the annual cost for treatment of diabetes is also high, and thus is an obstacle in the treatment of diabetes.
However, oxyntomodulin has a problem in that it should be administered at a high dose, because it has a short half-life in vivo and the activity thereof is insufficient for use in the treatment of obesity, diabetes, hyperlipidemia and fatty liver disease.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A composition for treating diabetes or diabesity comprising oxyntomodulin analog
  • A composition for treating diabetes or diabesity comprising oxyntomodulin analog
  • A composition for treating diabetes or diabesity comprising oxyntomodulin analog

Examples

Experimental program
Comparison scheme
Effect test

example 1

Production of Cell Line for In Vitro Activation

example 1-1

Production of Cell Line Showing cAMP Response to GLP-1

[0095]Using a portion corresponding to the ORF (open reading frame) of cDNA (OriGene Technologies, Inc. USA) of the human GLP-1 receptor gene as a template, PCR was performed using reverse and forward primers including a HindIII cleavage site and an EcoRI cleavage site, respectively, thereby obtaining a PCR product.

Forward primer:(SEQ ID NO: 50)5′-CCCGGCCCCCGCGGCCGCTATTCGAAATAC-3′Reverse primer:SEQ ID NO: 51)5′-GAACGGTCCGGAGGACGTCGACTCTTAAGATAG-3′

[0096]The PCR product was cloned into the known animal cell expression vector x0GC / dhfr, thereby constructing the recombinant vector x0GC / GLP-1R.

[0097]The recombinant vector x0GC / GLP-1R was introduced into a CHO DG44 cell line, cultured in DMEM / F12 (10% FBS) medium, using lipofectamine (Invitrogene, USA), to obtain a transformant. The transformant was incubated in a selective medium containing 1 mg / mL G418 and 10 nM methotraxate, and monoclonal cell lines were selected therefrom. Then, a...

example 1-2

Production of Cell Line Showing cAMP Response to Glucagon

[0098]Using a portion corresponding to the ORF (open reading frame) of cDNA (OriGene Technologies, Inc. USA) of the human glucagon receptor gene as a template, PCR was performed using reverse and forward primers including an EcoRI cleavage site and a XhoI cleavage site, respectively, thereby obtaining a PCR product.

Forward primer:(SEQ ID NO: 52)5′-CAGCGACACCGACCGTCCCCCCGTACTTAAGGCC-3′Reverse Primer:(SEQ ID NO: 53)5′-CTAACCGACTCTCGGGGAAGACTGAGCTCGCC-3′

[0099]The PCR product was cloned into the known animal cell expression vector x0GC / dhfr, thereby constructing the recombinant vector x0GC / GCGR.

[0100]The recombinant vector x0GC / GCGR was introduced into a CHO DG44 cell line, cultured in DMEM / F12 (10% FBS) medium, using lipofectamine (Invitrogene, USA), to obtain a transformant. The transformant was incubated in a selective medium containing 1 mg / mL G418 and 10 nM methotraxate, and monoclonal cell lines were selected therefrom. Then...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
weightaaaaaaaaaa
body weightaaaaaaaaaa
resistanceaaaaaaaaaa
Login to View More

Abstract

Disclosed are a composition for preventing or treating diabetes, diabesity or diabetic complications, containing an oxyntomodulin analog as an active ingredient and a method for treating diabetes, diabesity or diabetic complications, including administering a pharmaceutically effective amount of an oxyntomodulin analog to a subject. The oxyntomodulin analog shows a greater activity to activate a GLP-1 receptor and a glucagon receptor, than native oxyntomodulin. The oxyntomodulin analog induces an expansion of beta-cells and increases insulin secretion, thereby reducing blood glucose levels that were increased due to a high-calorie and high-fat diet. The oxyntomodulin analog induces decreases in a body weight and appetite to improve insulin sensitivity and is useful in maintaining normal blood glucose levels.

Description

TECHNICAL FIELD[0001]The present invention relates to a composition for preventing or treating diabetes, diabesity or diabetic complications, the composition comprising an oxyntomodulin analog as an active ingredient. Moreover, the present invention relates to a method for preventing or treating diabetes, diabesity or diabetic complications, the method comprising administering a pharmaceutically effective amount of an oxyntomodulin analog to a subject.BACKGROUND ART[0002]In recent years, in Korea, the intake of fats from foods has increased due to economic growth and the westernization of eating habits, and metabolic diseases such as hyperlipidemia, obesity, diabetes, hypertension, arteriosclerosis, and fatty liver disease, which are caused by a lack of exercise, have increased.[0003]Diabetes is a kind of metabolic disease in which insulin secretion is insufficient or normal functions are not made (DeFronzo, 1988). Diabetes is characterized by increased blood glucose levels that cau...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C07K14/575A61K47/48A61K38/22C07K16/00
CPCC07K14/575C07K16/00A61K47/48284C07K2319/31A61K38/22C07K2319/30A61K47/48292A61P3/10A61K38/26A61K39/395C07K14/605A61K47/643A61K47/6435C07K16/3046A61P3/04
Inventor KIM, JIN SUNKIM, DAE JINLEE, SANG HYUNJUNG, SUNG YOUBKWON, SE CHANG
Owner HANMI PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com